Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Neoplasms 5Polycythemia Vera 4Lung Neoplasms 4Ovarian Neoplasms 3Myeloproliferative Disorders 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Prostatic Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Adenocarcinoma 2Urticaria 1Tuberous Sclerosis 1Thymic aplasia 1Thrombosis 1Squamous Cell Carcinoma of Head and Neck 1Smoking 1Small Cell Lung Carcinoma 1Severe Combined Immunodeficiency 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1Primary Dysautonomias 1Polycythemia 1Polycystic Ovary Syndrome 1Pancreatitis, Chronic 1

Interventions

Cyclophosphamide 87fludarabine phosphate 86Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 58Tacrolimus 57Busulfan 57Whole-Body Irradiation 55Antilymphocyte Serum 47Cyclosporine 46fludarabine 39Methotrexate 38Filgrastim 38Melphalan 32ruxolitinib 30Cytarabine 30Radiotherapy 27Azacitidine 23Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Specimen Handling 15Sirolimus 15Granulocyte Colony-Stimulating Factor 15Decitabine 15Biopsy 15Flow Cytometry 14Cyclosporins 14Alemtuzumab 14thymoglobulin 13venetoclax 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Phlebotomy × Clear all
NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

PharmaEssentia Japan K.K.

Phase 2 Completed
29 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06290765 2025-07-31

PV

PharmaEssentia

Phase 4 Not yet recruiting
70 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

NCT06002490 2024-11-08

A Study to Evaluate P1101 in Japanese PV Patients

PharmaEssentia Japan K.K.

Phase 3 Completed
21 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡